Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer
| Autor: | Eduardo Fernandez, Constantine A. Mantz, N. Shore, Francisco A. Myslicki, Candice McCoy, Daniel E. Dosoretz, Steven E. Finkelstein, Mayer Fishman |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
PCA3
Oncology Male medicine.medical_specialty medicine.medical_treatment T-Lymphocytes Antigen-Presenting Cells Asymptomatic Cancer Vaccines Prostate cancer Internal medicine medicine Combined Modality Therapy Humans Orchiectomy Leukapheresis business.industry Tissue Extracts Cancer Prostatic Neoplasms Hematology General Medicine Immunotherapy medicine.disease Sipuleucel-T Leukocytes Mononuclear medicine.symptom business medicine.drug |
| Zdroj: | Cancer control : journal of the Moffitt Cancer Center. 20(1) |
| ISSN: | 1526-2359 |
| Popis: | Sipuleucel-T is an autologous cellular immunotherapy approved by the US Food and Drug Administration for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Its mechanism of action is based on stimulation of the patient's own immune system to target prostate cancer. Peripheral blood mononuclear cells, including antigen-presenting cells and T cells, are obtained from patients via leukapheresis and treated ex vivo with PA2024, a fusion protein consisting of prostatic acid phosphatase/granulocyte-macrophage colony-stimulating factor antigen.Data relating to the potential pharmacodynamic biomarkers associated with sipuleucel-T activity are reviewed, as well as considerations for patient selection and for sequencing sipuleucel-T with other prostate cancer treatments. Possible directions for future development are also discussed, including treatment of less advanced prostate cancer populations, combination treatment, and immune modulation.Data from three randomized, double-blind, placebo-controlled phase III clinical trials of sipuleucel-T in patients with metastatic castration-rresistant prostate cancer have shown improvement in overall survival vs control. Here, we review its developing role in prostate cancer therapy and future directions for development.There is potential to build on sipuleucel-T to further advance immunotherapy of prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|